Other Indications. For Joint Development Compounds whose indications do not fall within Chiron Indications, PathoGenesis Indications or Joint Indications, the Parties shall mutually decide which Party will constitute the most advantageous and effective developing Party, or whether both Parties should jointly develop such Joint Development Compound, when exercising the Development Option. If the Parties are unable to agree mutually on a developing Party, Chiron and PathoGenesis shall jointly develop the Joint Development Compound.
Appears in 3 contracts
Sources: Collaboration Agreement (Pathogenesis Corp), Collaboration Agreement (Pathogenesis Corp), Collaboration Agreement (Pathogenesis Corp)